TL;DR
Researchers report that a drug targeting the KRAS gene, daraxonrasib, roughly doubled survival times in metastatic pancreatic cancer patients, marking a significant advancement. While promising, further studies are needed to confirm long-term benefits and broader applicability.
Researchers have announced that a drug called daraxonrasib, which targets the KRAS gene, has roughly doubled survival times for patients with metastatic pancreatic cancer, from about seven months to 13 months on average. This development marks a potential turning point in a disease long regarded as nearly incurable, offering new hope for patients and clinicians.
The clinical trial, already reported in the New York Times, involved patients who had already undergone chemotherapy. The drug, a KRAS inhibitor, showed promising results, with survival nearly doubling compared to previous averages. Experts involved in the study say this is the first time a targeted therapy has demonstrated such a significant impact on pancreatic cancer prognosis.
Dr. Anirban Maitra, director of NYU Langone’s Laura and Isaac Perlmutter Cancer Center, emphasized that this breakthrough provides a foundation for further research. He noted that pancreatic cancer has historically been difficult to treat due to the gene KRAS being considered ‘undruggable,’ and that most treatments failed in clinical trials over decades.
Why It Matters
This development matters because pancreatic cancer has one of the highest mortality rates among cancers, with nearly 90% of patients dying within five years of diagnosis. Doubling survival time could translate into more meaningful life extension for patients and opens new avenues for targeted therapies in a disease once deemed nearly untreatable.
While this is an encouraging step, experts caution that more research is needed to confirm long-term benefits, understand potential side effects, and determine if the drug can be effective earlier in the disease course or in combination with other treatments.
PANCREATIC CANCER: YOUR JOURNEY, YOUR CHOICES: A Patient-Centered Guide to Diagnosis, Treatment, Nutrition, Symptom Management, and Living Well Every Day
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Background
Pancreatic cancer has long been a ‘graveyard’ for drug development, with few effective treatments available. The gene KRAS, identified in the 1980s, was seen as a key driver of the disease but was considered ‘undruggable’ for decades. Recent advances in molecular biology and drug design have begun to challenge that notion. Prior efforts focused on early detection and risk identification, as the pancreas’s deep location makes early diagnosis difficult. Blood tests and AI-driven imaging analysis are improving early detection capabilities, but effective treatments remained elusive until now.
“For the first time, there is some optimism in this disease. We finally have the foundation on which to build.”
— Dr. Anirban Maitra
“The data suggest that targeting KRAS can meaningfully extend survival in metastatic pancreatic cancer, a breakthrough in a field long marked by failure.”
— Research team spokesperson
What Remains Unclear
It is not yet clear whether the drug will be effective in a broader patient population or in earlier stages of pancreatic cancer. Long-term survival data and potential side effects are still under investigation. Additionally, the trial results have not yet been peer-reviewed or published in a scientific journal, so independent validation is pending.
What’s Next
Further clinical trials are planned to confirm these findings, evaluate long-term outcomes, and explore combination therapies. Regulatory approval processes will follow, and researchers aim to refine patient selection criteria to maximize benefit. Meanwhile, efforts continue to improve early detection methods, which are crucial for improving overall survival rates.
Key Questions
What is daraxonrasib and how does it work?
Daraxonrasib is a targeted drug that inhibits the KRAS gene, which drives tumor growth in many cancers, including pancreatic cancer. It works by blocking the gene’s activity, potentially halting or slowing disease progression.
How significant is this survival increase?
The clinical trial reported an increase from approximately seven months to 13 months of survival on average, nearly doubling the previous prognosis for metastatic pancreatic cancer patients.
Is this treatment available now?
No, the drug is still in the experimental stage. Further trials, peer review, and regulatory approval are required before it can become widely available.
Does this mean pancreatic cancer is now curable?
No, this is an important step forward but not a cure. It extends survival significantly in some cases, but pancreatic cancer remains a highly aggressive disease requiring continued research.
Source: Vox
